A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results

被引：1
|
作者：
Dieras, V.
Harbeck, N.
Albain, K.
Burris, H.
Awada, A.
Crivellari, D.
Andre, F.
Choi, Y. J.
Huang, J.
Miller, K. D.
机构：
[1] Inst Curie, Paris, France
[2] Univ Cologne, Cologne, Germany
[3] Loyola Univ, Maywood, IL 60153 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Ctr Riferimento Oncol, Aviano, Italy
[7] Inst Gustave Roussy, Villejuif, France
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] IU Simon Canc Ctr, Indianapolis, IN USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).
    De Wit, M
    Harbeck, N
    Thomssen, C
    Becker, K
    Psonka, A
    Hoffmann, R
    Villena, C
    Schutte, M
    Hossfeld, DK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 84S - 84S
  • [22] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
    Jin, Jin
    Wang, Bei
    Gao, Yuying
    Samant, Meghan
    Li, Chunze
    Song, Chunyan
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2010, 10 (06) : 489 - 491
  • [25] Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.
    Modi, Shanu
    Elias, Anthony D.
    LoRusso, Patricia
    Samant, Meghna
    Guardino, Ellie
    Althaus, Betsy
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] A phase Ib study of neratinib, pertuzumab, and trastuzumab with paclitaxel in patients with metastatic and locally advanced breast cancer
    Al-Awadhi, A.
    Kono, M.
    Marx, A.
    Moseley, T.
    Willey, J.
    Sun, H.
    Fu, M.
    Whitman, G. J.
    Valero, V.
    Ueno, N. T.
    Lim, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [28] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [29] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer
    Cascetta, Krystal P.
    Poulikakos, Poulikos
    Shapiro, Charles
    Fasano, Julie
    Bhardwaj, Aarti
    Irie, Hanna
    Goel, Anupama
    Klein, Paula
    Adams, Sylvia
    Kalinsky, Kevin
    Vahdat, Linda
    Ru, Meng
    Tiersten, Amy
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
    Gelmon, K. A.
    Fumoleau, P.
    Verma, S.
    Wardley, A. M.
    Conte, P. F.
    Miles, D.
    Gianni, L.
    McNally, V. A.
    Ross, G.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345